128 related articles for article (PubMed ID: 32740650)
1. Prosigna® breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK™) index for breast cancer prognosis.
Baskota SU; Dabbs DJ; Clark BZ; Bhargava R
Mod Pathol; 2021 Jan; 34(1):70-76. PubMed ID: 32740650
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.
Ono M; Tsuda H; Yunokawa M; Yonemori K; Shimizu C; Tamura K; Kinoshita T; Fujiwara Y
Breast Cancer; 2015 Mar; 22(2):141-52. PubMed ID: 23584595
[TBL] [Abstract][Full Text] [Related]
3. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.
Guarneri V; Piacentini F; Ficarra G; Frassoldati A; D'Amico R; Giovannelli S; Maiorana A; Jovic G; Conte P
Ann Oncol; 2009 Jul; 20(7):1193-8. PubMed ID: 19221152
[TBL] [Abstract][Full Text] [Related]
4. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
6. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
[TBL] [Abstract][Full Text] [Related]
7. Oncotype DX and Prosigna in breast cancer patients: A comparison study.
Abdelhakam DA; Hanna H; Nassar A
Cancer Treat Res Commun; 2021; 26():100306. PubMed ID: 33444922
[TBL] [Abstract][Full Text] [Related]
8. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
[TBL] [Abstract][Full Text] [Related]
9. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer.
Billgren AM; Tani E; Liedberg A; Skoog L; Rutqvist LE
Breast Cancer Res Treat; 2002 Jan; 71(2):161-70. PubMed ID: 11881912
[TBL] [Abstract][Full Text] [Related]
11. Use of the Gene Expression Test Prosigna
Ziegler C; Sotlar K; Hofmann DM; Kolben T; Harbeck N; Wuerstlein R
Breast Care (Basel); 2024 Feb; 19(1):34-42. PubMed ID: 38384489
[TBL] [Abstract][Full Text] [Related]
12. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis.
Loehberg CR; Almstedt K; Jud SM; Haeberle L; Fasching PA; Hack CC; Lux MP; Thiel FC; Schrauder MG; Brunner M; Bayer CM; Hein A; Heusinger K; Heimrich J; Bani MR; Renner SP; Hartmann A; Beckmann MW; Wachter DL
Breast Cancer Res Treat; 2013 Apr; 138(3):899-908. PubMed ID: 23479421
[TBL] [Abstract][Full Text] [Related]
15. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.
Rudolph P; Alm P; Heidebrecht HJ; Bolte H; Ratjen V; Baldetorp B; Fernö M; Olsson H; Parwaresch R
J Natl Cancer Inst; 1999 Feb; 91(3):271-8. PubMed ID: 10037106
[TBL] [Abstract][Full Text] [Related]
16. Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: A study from North India.
Marwah N; Batra A; Marwah S; Gupta V; Shakya S; Sen R
J Cancer Res Ther; 2018; 14(3):537-542. PubMed ID: 29893312
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer.
Arima N; Nishimura R; Osako T; Nishiyama Y; Fujisue M; Okumura Y; Nakano M; Tashima R; Toyozumi Y
Oncology; 2016; 90(1):43-50. PubMed ID: 26613521
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting sentinel lymph node metastasis in Turkish breast cancer patients: Predictive value of Ki-67 and the size of lymph node.
Ozemir IA; Orhun K; Eren T; Baysal H; Sagiroglu J; Leblebici M; Ceyran AB; Alimoglu O
Bratisl Lek Listy; 2016; 117(8):436-41. PubMed ID: 27546694
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of extranodal extension in axillary lymph node-positive breast cancer.
Ma X; Yang X; Yang W; Shui R
Sci Rep; 2021 May; 11(1):9534. PubMed ID: 33953240
[TBL] [Abstract][Full Text] [Related]
20. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
